Rapt Therapeutics (NASDAQ:RAPT) Upgraded at Wall Street Zen

Rapt Therapeutics (NASDAQ:RAPT) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other research analysts also recently issued reports about the stock. HC Wainwright increased their target price on shares of Rapt Therapeutics to $27.00 and gave the company a “buy” rating in a research report on Thursday, July 10th. JPMorgan Chase & Co. raised shares of Rapt Therapeutics from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a research report on Wednesday, July 30th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $38.00 target price (down from $51.00) on shares of Rapt Therapeutics in a research report on Friday, August 8th. Zacks Research downgraded shares of Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 22nd. Finally, UBS Group set a $9.00 target price on shares of Rapt Therapeutics and gave the company a “neutral” rating in a research report on Tuesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.57.

Rapt Therapeutics Trading Up 3.3%

Shares of RAPT opened at $16.22 on Friday. Rapt Therapeutics has a twelve month low of $5.67 and a twelve month high of $26.56. The firm’s fifty day simple moving average is $11.28 and its 200-day simple moving average is $9.23. The firm has a market capitalization of $268.28 million, a price-to-earnings ratio of -1.14 and a beta of -0.10.

Rapt Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.04). On average, analysts predict that Rapt Therapeutics will post -2.14 earnings per share for the current fiscal year.

Institutional Trading of Rapt Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. ADAR1 Capital Management LLC boosted its holdings in shares of Rapt Therapeutics by 408.4% in the first quarter. ADAR1 Capital Management LLC now owns 5,970,768 shares of the company’s stock valued at $7,284,000 after acquiring an additional 4,796,455 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in shares of Rapt Therapeutics by 303.1% in the first quarter. Nantahala Capital Management LLC now owns 5,012,927 shares of the company’s stock valued at $6,116,000 after purchasing an additional 3,769,414 shares during the period. AQR Capital Management LLC acquired a new stake in shares of Rapt Therapeutics in the first quarter valued at about $188,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Rapt Therapeutics by 112.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 150,946 shares of the company’s stock valued at $184,000 after purchasing an additional 79,967 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Rapt Therapeutics in the first quarter valued at about $143,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.